The link between Parkinson's disease and breast and prostate cancers: A meta-analysis

International Journal of Neuroscience

Volumn 125, Issue 12, 2015, Pages 895-903

  Wang, Tengfei ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

breast cancer; meta analysis; Parkinson's disease; prostate cancer

Indexed keywords

ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER RISK; CLINICAL OBSERVATION; ETHNICITY; GENDER; HUMAN; META ANALYSIS; MORBIDITY; PARKINSON DISEASE; PROSTATE CANCER; BIBLIOGRAPHIC DATABASE; BREAST NEOPLASMS; FEMALE; MALE; PROSTATIC NEOPLASMS; STATISTICS AND NUMERICAL DATA;

BREAST NEOPLASMS; DATABASES, BIBLIOGRAPHIC; FEMALE; HUMANS; MALE; PARKINSON DISEASE; PROSTATIC NEOPLASMS;

EID: 84946476489     PISSN: 00207454     EISSN: 15635279     Source Type: Journal    
DOI: 10.3109/00207454.2014.986265     Document Type: Article

References (30)

1. Doshay LJ. Problem situations in the treatment of paralysis agitans. J Am Med Assoc 1954;156:680-4.
2. Bajaj A, Driver JA, Schernhammer ES. Parkinson's disease and cancer risk: A systematic review and meta-analysis. Cancer Causes Control 2010;21:697-707.
3. Liu R, Gao X, Lu Y, Chen H. Meta-analysis of the relationship between Parkinson disease and melanoma. Neurology 2011;76:2002-9.
4. Bourque M, Dluzen DE, Di Paolo T. Neuroprotective actions of sex steroids in Parkinson's disease. Front Neuroendocrinol 2009;30:142-57.
5. Key TJ. Hormones and cancer in humans. Mutat Res 1995;333:59-67.
6. Ko YJ, Balk SP. Targeting steroid hormone receptor pathways in the treatment of hormone dependent cancers. Curr Pharm Biotechnol 2004;5:459-70.
7. Giovannelli P, Di Donato M, Giraldi T, et al. Targeting rapid action of sex steroid receptors in breast and prostate cancers. Front Biosci 2011;16:2224-32.
8. Qiu L-X, Yuan H, Yu K-D, et al. Glutathione S-transferase M1 polymorphism and breast cancer susceptibility: A metaanalysis involving 46,281 subjects. Breast Cancer Res Treat 2010;121:703-8.
9. CaiQ,Wang Z, Zhang W, et al. Association between glutathione S-transferases M1 and T1 gene polymorphisms and prostate cancer risk: A systematic review and meta-analysis. Tumour Biol 2014;35:247-56.
10. Wang T, Wang B. Association between Glutathione Stransferase M1/Glutathione S-transferase T1 polymorphisms and Parkinson's disease: A meta-analysis. J Neurol Sci 2014;338:65-70.
11. Minami Y, Yamamoto R, Nishikouri M, et al. Mortality and cancer incidence in patients with Parkinson's disease. J Neurol 2000;247:429-34.
12. Olsen JH, Friis S, Frederiksen K, et al. Atypical cancer pattern in patients with Parkinson's disease. Br J Cancer 2005;92:201-5.
13. Rugbjerg K, Friis S, Lassen CF, et al. Malignant melanoma, breast cancer and other cancers in patients with Parkinson's disease. Int J Cancer 2012;131:1904-11.
14. Kareus SA, Figueroa KP, Cannon-Albright LA, Pulst SM. Shared predispositions of parkinsonism and cancer: A population-based pedigree-linked study. Arch Neurol 2012;69:1572-7.
15. Elbaz A, Peterson BJ, Yang P, et al. Nonfatal cancer preceding Parkinson's disease: A case-control study. Epidemiology 2002;13:157-64.
16. Olsen JH, Friis S, Frederiksen K. Malignant melanoma and other types of cancer preceding Parkinson disease. Epidemiology 2006;17:582-7.
17. Lo RY,TannerCM, VanDen Eeden SK, et al.Comorbid cancer in Parkinson's disease. Mov Disord 2010;25:1809-17.
18. Becker C, Brobert GP, Johansson S, et al. Cancer risk in association with Parkinson disease: A population-based study. Parkinsonism Relat Disord 2010;16:186-90.
19. Fois AF, Wotton CJ, Yeates D, et al. Cancer in patients with motor neuron disease, multiple sclerosis and Parkinson's disease: record linkage studies. J Neurol Neurosurg Psychiatry 2010;81:215-21.
20. Mullen B, Muellerleile P, Bryant B. Cumulative meta-analysis: A consideration of indicators of sufficiency and stability. Pers Soc Psychol Bull 2001;27:1450-62.
21. D'Amelio M, Ragonese P, Morgante L, et al. Tumor diagnosis preceding Parkinson's disease: A case-control study.Mov Disord 2004;19:807-11.
22. Powers KM, Smith-Weller T, Franklin GM, et al. Diabetes, smoking, and other medical conditions in relation to Parkinson's disease risk. Parkinsonism Relat Disord 2006;12:185-9.
23. Sun L-M, Liang J-A, Chang S-N, et al. Analysis of Parkinson's disease and subsequent cancer risk in Taiwan: A nationwide population-based cohort study. Neuroepidemiology 2011;37:114-9.
24. Alcalay RN, Clark LN, Marder KS, Bradley WEC. Lack of association between cancer history and PARKIN genotype: A family based study in PARKIN/Parkinson's families. Genes Chromosomes Cancer 2012;51:1109-13.
25. Wirdefeldt K, Weibull CE, Chen H, et al. Parkinson's disease and cancer: A register-based family study. Am J Epidemiol 2014;179:85-94.
26. Elbaz A, Peterson BJ, Bower JH, et al. Risk of cancer after the diagnosis of Parkinson's disease: A historical cohort study. Mov Disord 2005;20:719-25.
27. Driver JA, Logroscino G, Buring JE, et al. A prospective cohort study of cancer incidence following the diagnosis of Parkinson's disease. Cancer Epidemiol Biomarkers Prev 2007;16: 1260-5.
28. Beyrouti MI, Beyrouti R, Beyrouti R, et al. Breast cancer in men. Presse Med. 2007;36:1919-24.
29. Andres SA, Smolenkova IA, Wittliff JL. Gender-associated expression of tumor markers and a small gene set in breast carcinoma. Breast 2014;23:226-33.
30. Wang T. Meta-analysis of PvuII, XbaI variants in ESR1 gene and the risk of Alzheimer's disease: The regional European difference. Neurosci Lett 2014;574C:41-6.